Abstract

Anti-IgE therapeutics interfere with the ability of IgE to bind to its receptors on effector cells. Here we report the crystal structure of an anti-IgE single-domain antibody in complex with an IgE Fc fragment, revealing how the antibody inhibits interactions between IgE and the two receptors FcεRI and CD23. The epitope overlaps only slightly with the FcεRI-binding site but significantly with the CD23-binding site. Solution scattering studies of the IgE Fc reveal that antibody binding induces a half-bent conformation in between the well-known bent and extended IgE Fc conformations. The antibody acts as functional homolog of CD23 and induces a closed conformation of IgE Fc incompatible with FcεRI binding. Notably the antibody displaces IgE from both CD23 and FcεRI, and abrogates allergen-mediated basophil activation and facilitated allergen binding. The inhibitory mechanism might facilitate strategies for the future development of anti-IgE therapeutics for treatment of allergic diseases.

Highlights

  • Anti-IgE therapeutics interfere with the ability of IgE to bind to its receptors on effector cells

  • Structure of IgE Fc bound by two single-domain antibodies

  • Residual binding of omalizumab to 026 sdab bound IgE Fc suggests a partial overlap of the 026 sdab epitope with the omalizumab epitope

Read more

Summary

Introduction

Anti-IgE therapeutics interfere with the ability of IgE to bind to its receptors on effector cells. The antibody acts as functional homolog of CD23 and induces a closed conformation of IgE Fc incompatible with FcεRI binding. The antibody displaces IgE from both CD23 and FcεRI, and abrogates allergen-mediated basophil activation and facilitated allergen binding. The inhibitory mechanism might facilitate strategies for the future development of anti-IgE therapeutics for treatment of allergic diseases. Allergic diseases can be linked to IgE antibodies present in the circulation and on the surface of a variety of cell types[1]. Strategies to reduce increased levels of IgE and to limit effector cell degranulation included the development of antagonistic antiIgE antibodies and antibody alternatives including a DARPin and aptamers[7]. Basic structural and functional aspects of anti-IgE, e.g., the mechanism of rapid improvement in chronic urticaria, remain unclear[16,17]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call